Introduction
The receptors for Fc portions of immunoglobulins (FcR) mediates various immune responses upon binding to antibodies or immune complexes [1, 2] . Mice deficient in FcR genes for IgG (FcgRI, FcgRII, FcgRIII) and IgE (FceRI, FceRII) have revealed their physiological roles in immune responses in vitro and in vivo [3, 4] .
Although functional Fc receptors for IgM had been reported on subpopulations of human and rodent T, B and NK cells [5] [6] [7] [8] [9] [10], a gene encoding an Fcμ receptor had not previously been identified. We finally cloned a novel Fc receptor for IgM, which was found to be also an Fc receptor for IgA, designated Fca/m receptor (Fca/mR) [11, 12] . The Fca/mR is a type I transmembrane protein with an immunoglobulin (Ig)-like domain in the extracellular portion, and is expressed on B cells and macrophages [11, 12] . The Fca/mR is an only IgM receptor identified on human and murine hematopoietic cells to date, and is thought to play a central role for immune responses mediated by IgM and IgA [13] .
The Fca/mR genes were mapped to syntenic regions of mouse chromosome Cho, et al 4 1 (1F) and human chromosome 1 (1q32.3), near several other Fc receptors, including Fcγ receptors I, II, and III, Fcε receptor, and the polymeric Ig receptor (poly-IgR) [11] .
The poly-IgR gene, another Fc receptor for IgM and IgA expressed on mucosal epithelial cells [14] , is only 12 kbp apart from the Fca/mR in the Fc receptor gene cluster on chromosome 1 [15] , suggesting that these two receptors seem to be closely related in their phylogenies. The polyIgR contains five Ig-like domains in the extracellular portion. We found a motif in the immunoglobulin (Ig)-like domain of human and mouse Fca/mR that is conserved in the first Ig-like domain of human, mouse and rat poly-IgR [11] . Although this region is important for IgM and IgA binding to the poly-IgR [14] , the molecular and structural characteristics of IgA and IgM binding to Fca/mR has been unclear.
We have recently established twelve monoclonal antibodies (mAbs) against mouse Fca/mR (mFca/mR), some of which efficiently block the IgM and IgA bindings to Fca/mR. By using these mAbs, we analyzed the molecular characteristics of the ligand binding by Fca/mR.
Materials and Methods

Cells, mice, antibodies and peptides
Ba/F3 and BW5147 is mouse pro-B and thymoma cell lines, respectively. The Ba/F3 and BW5147 transfectants stably expressing mFca/mR were established, as described [11] . Mice deficient in Fca/mR gene were established by using gene targeting strategy of ES cells (manuscript for preparation). Cho, et al 8
Results and Discussion
Establishment of mAbs against the mFca/mR
Although we had been trying to generate mAbs against mFca/mR by immunizing rats with the Ba/F3 transfectant expressing mFca/mR several times, we could generate only one anti-mFca/mR mAb (TX6) [11] . Furthermore, we could never generated anti-human Fca/mR (hFca/mR) mAb by immunizing mice with the hFca/mR antigens. Because amino acid sequences of extracellular domain of Fca/mR are highly conserved among human, mouse and rat (80.2% identity between mouse and rat and 51.3% between mouse and human) [11] , we considered that the immunological tolerance against Fca/mR antigens may be a cause of difficulty for establishing anti-human and mouse Fca/mR mAbs. In order to avoid immunological tolerance against mFca/mR antigens, we immunized a mouse deficient in Fca/mR gene, instead of rat or other species of animals, for generation of anti-mFca/mR with the mFca/mR-expressing Ba/F3 transfectant and successfully generated twelve anti-mFca/mR mAbs, designated TX57 to TX68 ( Table 1) .
Characterization of recognition sites by the anti-mFca/mR mAbs
To characterize recognition sites by the anti-Fca/mR mAbs, we performed competitive binding analysis, by using the BW5147 transfectant expressing mFca/mR.
The BW5147 transfectant was incubated with either mAb out of 12 mAbs generated and then stained with either biotinylated mAb, followed with FITC-conjugated streptavidin.
Analyses by flow cytometry demonstrated that any of mAbs, except TX57, did not interfere in the binding of TX57 to the transfectant (Fig 1A) . Similarly, TX64 binding to the transfectant was not inhibited by any of mAbs other than TX64 itself (Fig 1B) .
These results suggest that TX57 and TX64 mAbs recognize epitopes different from those recognized by the other mAbs. In contrast, TX58, TX59, TX60, TX61 and TX66 mAbs and TX67 and TX68 mAbs, but not the other mAbs, completely or partially inhibited the binding of these mAbs one another to the transfectant, respectively ( Fig   1C, D and Table 2) . Similarly, TX62, TX63 and TX65 mAbs, but not the other mAbs, interfered in the binding of these mAbs one another to the transfectant (Fig 1E and Table 1) .
Blocking of ligand binding to the Fca/mR by the anti-Fca/mR mAbs
Next, we examined whether IgM and IgA bindings to the mFca/mR could be Fca/mR that is conserved in the first Ig-like domain of human, mouse and rat poly-IgR (Fig 3A[11] ). Previous reports suggested that this motif is important for IgM and IgA bindings to the poly-IgR [16, 17] . Thus, this region is predicted to be also important for IgA and IgM bindings to the Fca/mR. To evaluate this possibility, we synthesized the peptides corresponding to this motif sequence (motif peptide) (Fig 3A) and to the chicken egg ovalbumin (OVA) as a control for competitive binding analyses. Each anti-mFca/mR mAb was preincubated with the motif or control peptides and then used for staining of the BW5147 transfectant expressing the Fca/mR. As demonstrated in (Table 1) . There is one amino acid difference between the motif peptide sequences of mouse and human Fca/mR (Fig 3A) , which might be involved in epitopes recognized by the mAbs in groups I and IV. It should be noted that, while the motif peptide is also highly conserved in mouse, human and rat poly-IgR (Fig 3A) , no mAbs in the group I to V cross-reacted to the mouse poly-IgR (data not shown).
In conclusion, by using mice deficient in Fca/mR gene, we have successfully 
